Investigational Drug Information for GDC-0152
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for GDC-0152?
GDC-0152 is an investigational drug.
There have been 188 clinical trials for GDC-0152.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 9th 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
There are sixty-five US patents protecting this investigational drug and one international patent.
Summary for GDC-0152
| US Patents | 65 |
| International Patents | 1,180 |
| US Patent Applications | 143 |
| WIPO Patent Applications | 45 |
| Japanese Patent Applications | 70 |
| Clinical Trial Progress | Phase 3 (2020-10-09) |
| Vendors | 29 |
Recent Clinical Trials for GDC-0152
| Title | Sponsor | Phase |
|---|---|---|
| Preoperative Window of Opportunity Study With Giredestrant (GDC-9545) or Tamoxifen in Premenopausal Women With ER[+]/HER2[-] & Ki67≥10% Early Breast Cancer | MedSIR | Phase 2 |
| A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | Genentech, Inc. | Phase 1/Phase 2 |
| A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) | Genentech, Inc. | Phase 1 |
Clinical Trial Summary for GDC-0152
Top disease conditions for GDC-0152
Top clinical trial sponsors for GDC-0152
US Patents for GDC-0152
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GDC-0152 | See Plans and Pricing | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (Cambridge, MA) | See Plans and Pricing |
| GDC-0152 | See Plans and Pricing | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | See Plans and Pricing |
| GDC-0152 | See Plans and Pricing | Bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | See Plans and Pricing |
| GDC-0152 | See Plans and Pricing | NAMPT and ROCK inhibitors | AbbVie Inc. (North Chicago, IL) | See Plans and Pricing |
| GDC-0152 | See Plans and Pricing | Bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GDC-0152
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GDC-0152 | China | CN108368161 | 2035-09-10 | See Plans and Pricing |
| GDC-0152 | European Patent Office | EP3347372 | 2035-09-10 | See Plans and Pricing |
| GDC-0152 | Japan | JP2018528217 | 2035-09-10 | See Plans and Pricing |
| GDC-0152 | World Intellectual Property Organization (WIPO) | WO2017044633 | 2035-09-10 | See Plans and Pricing |
| GDC-0152 | Argentina | AR095266 | 2033-03-12 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
